Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous mDC3/8-KRAS vaccine

An antineoplastic vaccine composed of autologous mature dendritic cells (mDCs) pulsed with mutant KRAS peptides specific to a patient's tumor mutation and human leukocyte antigen (HLA) type, with potential immunostimulating and antineoplastic activities. Upon administration, this vaccine, which is administered as an mDC3 primer, followed by an mDC8 booster, may elicit a cytotoxic T-cell (CTL) response against cancer cells expressing certain KRAS mutations. K-RAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutation of K-RAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous peptide-pulsed mDC3/8 KRAS vaccine
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search